Literature DB >> 19059803

Brain magnetic resonance imaging (MRI) in parkinsonian disorders.

Oraporn Sitburana1, William G Ondo.   

Abstract

Magnetic resonance imaging (MRI) is increasingly integrated into neurological diagnostics. In addition to functional MRI, a large number of sequences (T1W, T2W, PD, T2W gradient echo, diffusion-weighted imaging (DWI), and diffusion tensor imaging (DTI)), investigate CNS abnormalities. Objective quantification techniques (T1W voxel-based morphometry) can also discern subtle anatomical differences. Parkinsonian conditions such as Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and manganese-induced parkinsonism can clinically overlap, yet have very different prognoses and treatments. Relatively little radiographic interest has focused on movement disorders. Nevertheless in the past decade, a variety of findings, often subtle and routinely overlooked, have emerged to help the clinician differentiate these conditions. This review will summarize and discuss MRI findings in parkinsonian conditions. Most data concern either structural abnormalities or the imaging sequelae of abnormal iron deposition, common in some parkinsonian conditions.

Entities:  

Mesh:

Year:  2008        PMID: 19059803     DOI: 10.1016/j.parkreldis.2008.04.033

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

1.  Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractography.

Authors:  Pia Kvickström; Bengt Eriksson; Danielle van Westen; Jimmy Lätt; Christina Elfgren; Christer Nilsson
Journal:  BMC Neurol       Date:  2011-01-26       Impact factor: 2.474

2.  Patterns of focal gray matter atrophy are associated with bradykinesia and gait disturbances in older adults.

Authors:  Caterina Rosano; David A Bennett; Anne B Newman; Vijay Venkatraman; Kristine Yaffe; Tamara Harris; Stephen Kritchevsky; Howard J Aizenstein
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-24       Impact factor: 6.053

3.  [MRI in dementia-type diseases].

Authors:  S V Bodea; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

Review 4.  The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.

Authors:  T C Booth; M Nathan; A D Waldman; A-M Quigley; A H Schapira; J Buscombe
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-05       Impact factor: 3.825

5.  Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.

Authors:  João Massano; Kailash P Bhatia
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

6.  Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes.

Authors:  Jae-Hyeok Lee; Tae-Hyung Kim; Chi-Woong Mun; Tae-Hyoung Kim; Yong-Hee Han
Journal:  J Neurol       Date:  2015-05-28       Impact factor: 4.849

Review 7.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

8.  Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy.

Authors:  Myung Jun Lee; Tae-Hyung Kim; Chi-Woong Mun; Hae Kyung Shin; Jongsang Son; Jae-Hyeok Lee
Journal:  J Neurol       Date:  2018-04-25       Impact factor: 4.849

9.  History of falls in Parkinson disease is associated with reduced cholinergic activity.

Authors:  N I Bohnen; M L T M Müller; R A Koeppe; S A Studenski; M A Kilbourn; K A Frey; R L Albin
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

10.  Optical coherence tomography in parkinsonian syndromes.

Authors:  Philipp Albrecht; Ann-Kristin Müller; Martin Südmeyer; Stefano Ferrea; Marius Ringelstein; Eva Cohn; Orhan Aktas; Thomas Dietlein; Alexandra Lappas; Andreas Foerster; Hans-Peter Hartung; Alfons Schnitzler; Axel Methner
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.